Immunocore(US:IMCR) Yahoo Finance·2026-01-30 14:47Company Overview - Immunocore Holdings plc (NASDAQ:IMCR) is a biotechnology company focused on developing TCR bispecific immunotherapies for cancer, infectious diseases, and autoimmune conditions, utilizing its proprietary ImmTAX technology [4] Investment Potential - Analysts from H.C. Wainwright and UBS have reiterated a Buy rating for Immunocore, with price targets of $100 and $55 respectively, indicating strong confidence in the stock's future performance [1][2] - UBS highlights significant upside potential for the stock, as it is currently trading near the value of its approved drug Kimmtrak, suggesting that the market has not fully valued the company's upcoming phase 3 trials [2] Upcoming Trials - The company has two key upcoming trials: the TEBE-AM trial for second-line Kimmtrak in metastatic cutaneous melanoma, with data expected by late 2026 or early 2027, and the first-line PRAME trial, with data anticipated in late 2027 or 2028 [3] Market Impact - Positive results from the upcoming trials could potentially boost the stock by 25% to 50% and contribute an additional $300 million to $400 million in annual sales [2]